Hims & Hers Health Launches Peptides+ Platform Featuring Compounded Longevity Treatments

Hims & Hers Health (HIMS) has announced the rollout of its 'Peptides+' platform, offering five new compounded treatments including sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. These products are being launched following a federal easing of restrictions on compounding certain unapproved peptide products in the United States. While the company reported high consumer interest—with over 10,000 people joining an early access list within 15 days—management acknowledged significant clinical uncertainty. The treatments are not FDA-approved, and the company noted that more research is required to fully understand their efficacy and optimal usage. Hims & Hers plans to expand the platform in the future with additional peptides like BPC-157 and TB-500.

2 articles from 2 sources · updated

Coverage